

INBRIJA (levodopa inhalation powder)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

Parkinson's disease experiencing OFF episodes

AND ALL of the following:

- 1. Used in combination with carbidopa/levodopa
- 2. Inadequate control of Parkinson's symptoms on maximum tolerated doses of oral carbidopa/levodopa therapy
- 3. NO asthma or chronic obstructive pulmonary disease (COPD)
- NO concomitant use of a nonselective monoamine oxidase inhibitor (MAOI), such as phenelzine or tranylcypromine (must be >14 days post discontinuing therapy)

Prior - Approval Limits

Quantity

Medication	Quantity Limit
42 mg capsules	900 capsules per 90 days

Duration 6 months

Prior – Approval Renewal Requirements

Age 18 years of age or older



Federal Employee Program.

INBRIJA (levodopa inhalation powder)

Diagnosis

Patient must have the following:

Parkinson's disease experiencing OFF episodes

AND ALL of the following:

- 1. Improvement in Parkinson's symptoms
- 2. Used in combination with carbidopa/levodopa
- 3. NO asthma or chronic obstructive pulmonary disease (COPD)
- 4. NO concomitant use of a nonselective monoamine oxidase inhibitor (MAOI), such as phenelzine or tranylcypromine

Prior - Approval Renewal Limits

Quantity

Medication	Quantity Limit
42 mg capsules	900 capsules per 90 days

12 months Duration